Could Dividend Champions BAE Systems plc, Vodafone Group Plc And AstraZeneca Also Grow By 50%?

Can Vodafone Group Plc (LON: VOD), AstraZeneca Plc (LON: AZN) and BAE Systems Plc (LON: BA) break the mould to provide income and growth?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares paying high dividends are normally thought of as low-growth businesses, but could BAE Systems (LSE: BA), Vodafone (LSE: VOD) and AstraZeneca (LSE: AZN) reward shareholders with dividends paying over 4% and appreciate in value by 50% or more?

Winning bet?

BAE shareholders will welcome with open arms the increasing defence budgets in the UK, US, and Saudi Arabia, which together account for over 75% of sales. Due to these increased budgets, BAE may finally reverse five straight years of declining revenues when full-year results are announced next week. During this rebuilding phase management did well to cut costs and increase margins, which allowed earnings per share to remain level from 2010 to 2015 even as revenue fell 25%.

With major business lines much more profitable than they were prior to 2010 and year-on-year revenue finally due to increase, BAE shares could be in for significant upward rerating. Trading at a forward price/earnings multiple of 11.7, there’s room for the shares to grow to reach the levels of major US competitors Boeing and Lockheed Martin, which trade at 14 and 18 times earnings, respectively. This growth potential may not reach a full 50% over the medium term, but with a healthy 4.1% yielding dividend and better days ahead I believe BAE could be a winning bet for income investors.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

One to watch

Vodafone’s £20bn infrastructure investment programme, Project Spring, is finally coming to a close this year and has already begun to bear fruit for the mobile phone operator. 4G coverage has expanded from 32% to 80% of Europeans, opening up wide swathes of the continent to Vodafone’s highly profitable data packages.

Analysts are forecasting the possibility of 5% annual organic growth over the next five years. When combined with substantially lower capital expenditure, this is forecast to increase earnings by 19% next year alone. Furthermore, the 5.3% yielding dividend is now covered by earnings and holds the potential to rise alongside profits over the medium term. The bad news for intrigued investors is that much of this growth is baked into share prices already as they’re trading at 34 times projected 2017 earnings. Given current valuations, I don’t foresee the shares increasing in value by 50% over the medium term although Vodafone is still a share to watch.

Patent problems

Drug maker AstraZeneca was knocked back last week on poor guidance for 2016 after blockbuster cholesterol drug Crestor’s patent expired. With heartburn treatment Nexium losing its own patent later this year, AstraZeneca was forced to go on a $10bn buying spree last year to restock its drug pipeline. While the long-term prospects may be very good for AstraZeneca, as management is increasing R&D spending as well as M&A, I believe there will be further pain in the short term for prices.

It’s the nature of the pharmaceuticals industry that drugs take many years to develop before coming to market, and it could be years before AstraZeneca finds a replacement for Nexium and Crestor, which provided more than 35% of revenues last year. Share prices have been mostly flat for the past two years, allowing the P/E ratio to settle at a relatively attractive 15 times forward earnings. Shares may not skyrocket 50% anytime soon, but offer a 4.2% yield and are worth following over the next few years as more drugs go to trial.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

piggy bank, searching with binoculars
Investing Articles

With Rolls-Royce shares moving up again, is a £10 price target back on the horizon?

Rolls-Royce shares wobbled when President Trump dropped his tariff bombshell on us. But three weeks is a short time in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

2 UK stocks to consider buying as the market sell-off continues

Stephen Wright thinks investors looking for opportunities might be able to take advantage of short-term weakness in some UK stocks.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

1 stock for passive income investors to consider buying before the Bank of England cuts interest rates

With the Bank of England’s Monetary Policy Committee set to meet in May, passive income investors should think about how…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Is Tesla about to become the ultimate passive income machine?

Our writer discusses whether Tesla stock might be worth him buying, just in case the EV giant enables passive income…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Will the Rolls-Royce share price collapse? Here’s what the charts say

The Rolls-Royce share price has pulled back following the announcement of Donald Trump’s trade policy, but supportive trends remain.

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

The silver lining in a market downturn: passive income opportunities galore

The stock market has been rocked by Donald Trump’s trade and economic policy. Passive income investors may spy an opportunity…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

2 world-class growth stocks to consider buying in May

Following the recent market sell-off, this pair of top-tier growth stocks look attractive for long-term investors. Here's why.

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

2 stocks I plan to own until at least 2030!

Ben McPoland explains why he continues to hold this excellent pair of FTSE 100 companies in his Stocks and Shares…

Read more »